FDA approves Opdivo/Yervoy combo in first-line RCC: https://news.bms.com/press-release/corporatefinancial-news/us-food-and-drug-administration-approves-opdivo-nivolumab-yerv?linkId=50524011 Today was the PDUFA date. The approval is based on the CHECKPOINT-214 study (#msg-136010123). This approval was fully expected, and hence it’s doing nothing to arrest today’s sell-off.